Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by pabalooon Feb 04, 2020 3:53pm

82 Views

Post# 30641996

RE:RE:RE:RE:RE:RE:RE:RE:Absorbica Going To China and Japan??

They will never get full value in a fire sale but the big 3 should bring in 40 million plus that alone puts the company at 1.50 a share unless I'm missing something. It's too quiet here I'm thinking the news is coming and I don't think it's all positive or we would see a rise in valuation.

Bullboard Posts

Three stocks with strong income statements to buy right now